MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 28 – October 2, 2026 in Milan, Italy. Presented data will highlight SAB BIO’s lead program, SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.
“We are honored to present and participate at the EASD Annual Meeting, which provides an important opportunity to engage with the global diabetes community as type 1 diabetes research increasingly focuses on preserving endogenous insulin production and modifying the course of disease,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “Our presentations highlight SAB-142 Phase 1 data, including its mechanism of action, potential for safe redosing, and early evidence of C-peptide preservation. We look forward to engaging with the scientific community as SAB-142 continues to advance through the registrational SAFEGUARD study.”
Oral Presentations at EASD Annual Meeting 2026:
Title: SAB-142: Setting a New Standard for Beta-Cell Preservation
Session: INNODIA Symposium on Type 1 Diabetes Therapies
Presenter: Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO
Presentation Date and Time: Monday, September 28, 2026, 3:00 – 5:25 PM CEST
Location: Berlin Hall, Milan Convention Centre, Piazzale Carlo Magno 1, Milan, Italy
Title: Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with type 1 diabetes > 100 days post diagnosis*
Session: Can we stop type 1 diabetes?
Presenter: Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIO
Presentation Date and Time: Wednesday, September 30, 2026, 1:00 – 2:00 PM CEST
Location: Station 03, Milan Convention Centre, Piazzale Carlo Magno 1, Milan, Italy
Title: SAB-142, a fully human anti-thymocyte globulin, can be safely readministered, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers*
Session: Can we stop type 1 diabetes?
Presenter: William Quinn, PhD, Executive Director, Immunology, SAB BIO
Presentation Date and Time: Wednesday, September 30, 2026, 1:00 – 2:00 PM CEST
Location: Station 03, Milan Convention Centre, Piazzale Carlo Magno 1, Milan, Italy
Title: SAB-142, a fully human anti-thymocyte globulin, demonstrated anticipated PD profiles and early efficacy signals in T1D patients with residual C-peptide*
Session: Can we stop type 1 diabetes?
Presenter: William Quinn, PhD, Executive Director, Immunology, SAB BIO
Presentation Date and Time: Wednesday, September 30, 2026, 1:00 – 2:00 PM CEST
Location: Station 03, Milan Convention Centre, Piazzale Carlo Magno 1, Milan, Italy
*Each of these sessions will also be available as poster presentations (ePID2235, ePID2238, ePID2240) in the ePoster Area – North Wing, Central Building – in the Milan Convention Centre, Piazzale Carlo Magno 1, Milan, Italy.
The presentations will be made available in the Presentations section of the Company’s website afterwards and will remain accessible following the conference.
About SAB-142
SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of “bad acting” T-lymphocytes. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.
Forward-Looking Statements
Certain statements made in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs.
These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Investor Relations:
Christine Ryan
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
